Catalyst

Slingshot members are tracking this event:

Pfizer (PFE) initiates a Phase 3 open-label lead-in study evaluating current factor IX prophylaxis replacement therapy in the usual care setting for patients with hemophilia B

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PFE

100%

Additional Information

Additional Relevant Details The primary endpoint is change in annualized bleed rate from baseline over a six-month treatment period. According to ClinicalTrials.gov, the estimated completion date is November 2020
https://seekingalpha...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 16, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hemophilia B, Factor Ix